Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06143046 · ClinicalTrials.gov registry record · Phase 2
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
A Phase 2 study of Respiratory Syncytial Virus, sponsored by ModernaTX.
- Active
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06143046 is a Phase 2 study of Respiratory Syncytial Virus that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 360 participants, roughly in line with the 346-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target. The trial reports 20 study locations across 10 states.
The verdict
NCT06143046, a Phase 2 study of Respiratory Syncytial Virus, is active but no longer recruiting, sponsored by ModernaTX.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the reactogenicity, safety, and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine, mRNA-1345, in pregnant women, and safety and immunogenicity in infants born to vaccinated mothers.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1345
Study Locations (20)
California
- Matrix Clinical Research - Gardena - Gardena
- Matrix Clinical Research - Huntington Park - Huntington Park
- Matrix Clinical Research, Inc - Corporate Office - Los Angeles
Idaho
- Clinical Research Prime - ClinEdge - PPDS - Idaho Falls
- Bingham Memorial Hospital - Pocatello
- Clinical Research Prime - ClinEdge - Rexburg - PPDS - Rexburg
Montana
- Boeson Research GTF - Great Falls - ERN - PPDS - Great Falls
- Boeson Research KAL - Kalispell - ERN - PPDS - Kalispell
- Boeson Research MSO - Missoula - ERN - PPDS - Missoula
Nebraska
- Velocity Clinical Research (Grand Island - Nebraska) - PPDS - Grand Island
- Velocity Clinical Research (Hastings - Nebraska) - PPDS - Hastings
- Velocity Clinical Research (Norfolk - Nebraska) - PPDS - Norfolk
Arizona
- Abby's Research Institute - Phoenix
- Watching Over Mothers & Babies - Tucson
Texas
- DM Clinical Research - Bellaire - ERN - PPDS - Houston
- Maximos OB/GYN - League City
Alabama
- SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS - Dothan
Arkansas
- Applied Research Center of Arkansas - ClinEdge - PPDS - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2026-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06143046
The ClinicalTrials.gov registry entry for NCT06143046 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 346-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06143046 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Idaho, Montana.
Frequently Asked Questions
What is clinical trial NCT06143046 about?
NCT06143046 is a clinical study titled "A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers". The purpose of the study is to evaluate the reactogenicity, safety, and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine, mRNA-1345, in pregnant women, and safety and immunogenicity in infants born to vaccinated mothers.
What is the current status of trial NCT06143046?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2023-11-15. Estimated completion is 2026-05-27.
What conditions does trial NCT06143046 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus.
What interventions are being tested in trial NCT06143046?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1345 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06143046?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06143046 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
COMPLETED · Phase 2
-
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
COMPLETED · Phase 2
-
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
ACTIVE NOT RECRUITING · Phase 3
-
Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.